NCT00371553View on ClinicalTrials.gov

Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Relapsed or Cisplatin-Refractory Germ Cell Cancer
Interventions
DRUG

SU011248 (Sunitinib)

Trial Locations (6)

T4N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

R3E 0V9

Cancer Care Manitoba, Winnipeg

B3H 2Y9

QEII Health Science Center, Halifax

N6A 4L6

London Regional Cancer Centre, London

M5G2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Urologic Oncology Group

OTHER

collaborator

NCIC Testis Group

UNKNOWN

collaborator

German Testicular Cancer Study Group

OTHER

lead

British Columbia Cancer Agency

OTHER

NCT00371553 - Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer | Biotech Hunter | Biotech Hunter